AtriCure CTO Sells 3,657 Shares

CTO of AtriCure, Salvatore Privitera, sold 3,657 shares of the company's common stock on September 8, 2026, according to a recent SEC Form 4 filing. The transaction value, calculated based on the weighted average sale price of $55 per share, amounted to $201,015. However, the post-transaction value, determined by the market close on September 8, 2026, at $53.73 per share, reduced the value to $196,177.

AtriCure, a mid-cap medical device company valued at $2.7 billion, has shown robust operational momentum with $569.6 million in trailing twelve-month revenues. The company holds a specialized focus on the cardiac ablation market, utilizing proprietary radiofrequency and multifunctional device technologies for both therapeutic interventions and real-time diagnostics during surgical procedures.

With a workforce of 1,350 employees and an international distribution network, AtriCure aims to expand its market share within the expanding cardiac surgery and arrhythmia treatment sectors.